文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

视网膜母细胞瘤患者继发性肿瘤相关新生血管的临床特征与治疗结局

CLINICAL CHARACTERISTICS AND MANAGEMENT OUTCOMES OF SECONDARY TUMOR-ASSOCIATED NEOVASCULARIZATION IN RETINOBLASTOMA PATIENTS.
PubMed 文献 · Retina · 2026-01-01

单中心回顾性研究纳入11例视网膜母细胞瘤(RB)患者的12只眼,描述继发性肿瘤相关新生血管(STN)的临床特征,并评估玻璃体腔注射抗血管内皮生长因子(anti-VEGF)的结局与并发症。STN发病平均年龄15个月,11只眼在新生血管发生前接受过动脉内化疗(IAC)(平均6个周期,范围2-11个周期)。平均接受4.6次(范围1-18次)玻璃体腔anti-VEGF注射后,6只眼新生血管消退且无复发,5只眼新生血管消退但随访中复发,1只眼注射2次后新生血管未控制且拒绝进一步注射。常见并发症包括牵拉性视网膜脱离(n=6)和玻璃体膜(n=5),无眼需眼球摘除,所有患者存活且无眼外扩展或转移(平均随访64个月,范围37-112个月)。

要点

  • RB患者在接受多模式综合治疗(尤其IAC)后可发生STN,平均发病年龄15个月。
  • 玻璃体腔anti-VEGF注射有助于STN消退,但部分眼仍复发或未控制。
  • anti-VEGF治疗相关并发症包括牵拉性视网膜脱离和玻璃体膜,需认识并预见。

核心结论

  • STN可发生于接受多次综合治疗(尤其IAC)后的RB患者。
  • 玻璃体腔anti-VEGF注射有助于新生血管消退,但必须认识并预见anti-VEGF治疗相关并发症。

研究设计与样本

  • 单中心回顾性研究,纳入11例RB患者的12只眼。
  • 一旦眼底荧光血管造影确诊STN即给予玻璃体腔anti-VEGF注射,每月一次直至新生血管消退。
  • 记录人口学特征、临床特征、治疗结局及anti-VEGF治疗后的并发症。

主要发现

  • STN在11例RB患者的12只眼中检出,平均发病年龄15个月。
  • 11只眼在新生血管发生前接受过IAC(平均6个周期,范围2-11个周期)。
  • 平均接受4.6次(范围1-18次)玻璃体腔anti-VEGF注射后,6只眼新生血管减少且无复发;5只眼新生血管消退但随访中复发;1只眼注射2次后新生血管未控制且拒绝进一步注射。
  • anti-VEGF注射相关常见并发症包括牵拉性视网膜脱离(n=6)和玻璃体膜(n=5)。
  • 无眼需眼球摘除;所有患者存活,无眼外扩展或转移(平均随访64个月,范围37-112个月)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the clinical characteristics of secondary tumor-associated neovascularization (STN) in retinoblastoma (RB) patients and the outcomes and complications of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) in the treatment of STN. METHODS: A single-center retrospective study. Intravitreal injections of anti-VEGF were given to RB patients once STN was confirmed by fundus fluorescein angiography and performed monthly until neovascularization was resolved. Demographic characteristics, clinical characteristics, treatment outcomes, and complications after anti-VEGF therapy were recorded. RESULTS: STN was detected in 12 eyes of 11 RB patients with a mean age of onset of 15 months. Eleven eyes received intra-arterial chemotherapy (IAC) (mean: six cycles, range: 2-11 cycles) before neovascularization onset. After receiving a mean of 4.6 (range: 1-18) intravitreal anti-VEGF injections, six eyes first exhibited reduced neovascularization with no relapse; five eyes first achieved resolution of neovascularization, but recurrence was observed at follow-up; and one eye received two anti-VEGF injections, but control of neovascularization was not achieved and further injections were refused. Common complications related to anti-VEGF injection included tractional retinal detachment (n = 6) and hyaloid membranes (n =5). None of the eyes needed enucleation. All the patients were alive without extraocular extension or metastases (mean follow-up 64 months, range: 37-112 months). CONCLUSION: STN can occur in RB patients after multiple comprehensive therapies, especially IAC. Intravitreal anti-VEGF injection contributes to the resolution of neovascularization, but anti-VEGF treatment-related complications must be recognized and anticipated.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Fu J, Yang X, Yang J, et al. CLINICAL CHARACTERISTICS AND MANAGEMENT OUTCOMES OF SECONDARY TUMOR-ASSOCIATED NEOVASCULARIZATION IN RETINOBLASTOMA PATIENTS. Retina. 2026. PMID: 41212979. doi:10.1097/IAE.0000000000004722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。